Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA-Naïve and ESA-Treated Chronic Kidney Disease Patients With Renal Anemia-Reference-Cited by-同舟云学术

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA-Naïve and ESA-Treated Chronic Kidney Disease Patients With Renal Anemia

Published:2010-05 Issue:5 Volume:50 Page:507-520
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Chanu Pascal,Gieschke Ronald,Charoin Jean-Eric,Pannier Anne,Reigner Bruno

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference19 articles.

1. Pharmacokinetic/pharmacodynamic modeling in drug development;Sheiner;Annu Rev Pharmacol Toxicol,2000

2. Pharmacokinetic/pharmacodynamic modeling in drug research and development;Derendorf;J Clin Pharmacol,2000

3. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure;Locatelli;Nephrol Dial Transplant,2004

4. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease;National Kidney Foundation;Am J Kidney Dis,2006

5. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay;Jarsch;Pharmacology,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Growth Factors;Pharmaceutical Biotechnology;2024

2. Evaluation of Hemoglobin Response to Treatment With Enarodustat Using Pharmacometric Approach in Japanese Anemic Patients With Chronic Kidney Disease;The Journal of Clinical Pharmacology;2022-10-07

3. Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease;British Journal of Clinical Pharmacology;2020-01-21

4. Hematopoietic Growth Factors;Pharmaceutical Biotechnology;2019

5. Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis;Clinical and Experimental Pharmacology and Physiology;2016-09-01